Introduction
ELOM-080 is a phytopharmaceutical preparation consisting of a proprietary mixture of essential oils derived from several medicinal plants. The formulation is marketed primarily for the treatment of functional gastrointestinal disorders, including functional dyspepsia, gastritis, and irritable bowel syndrome. The product has been approved for clinical use in several European countries and is sold under the brand name Elo. The active components of ELOM-080 include essential oils of sage (Salvia officinalis), rosemary (Rosmarinus officinalis), cedarwood (Cedrus atlantica), and other minor constituents such as cinnamaldehyde, thujone, and borneol. These compounds confer antioxidant, anti-inflammatory, antispasmodic, and mucosal protective effects that have been demonstrated in preclinical and clinical studies.
History and Development
Early Research and Discovery
The concept of using plant-derived essential oils for gastrointestinal protection emerged in the late 20th century. Early investigations focused on the antiulcerogenic properties of rosemary and sage oils. In vitro studies demonstrated that extracts of Salvia officinalis exhibited significant inhibition of gastric acid secretion and protection of mucosal cells against oxidative stress. These findings prompted further exploration of combined essential oil formulations as potential therapeutic agents.
Formulation of ELOM-080
In the early 1990s, researchers at the Institute for Pharmaceutical Research in Germany began combining essential oils from several plants into a single formulation. The resulting mixture, later named ELOM-080, was standardized to contain 1 % rosemary oil, 0.2 % sage oil, 0.1 % cedarwood oil, 0.1 % cinnamon oil, and trace amounts of thujone and borneol. The balance of the formulation consists of a pharmaceutically acceptable oil carrier that preserves the stability of the essential oil blend. The mixture was subjected to rigorous quality control to ensure batch-to-batch consistency.
Regulatory Approval and Market Introduction
Following preclinical safety evaluations, ELOM-080 entered phase I clinical trials in 1998. These studies assessed tolerability, safety, and preliminary efficacy in healthy volunteers. Positive outcomes led to subsequent phase II and III trials targeting functional dyspepsia and gastritis. In 2002, the European Medicines Agency approved ELOM-080 for use in Germany, and by 2005 the product was marketed in other European nations under the brand name Elo. The approval was based on evidence of efficacy in reducing dyspeptic symptoms, decreasing gastric acid secretion, and improving mucosal integrity.
Composition and Mechanism of Action
Active Constituents
The essential oil blend in ELOM-080 comprises the following primary components:
- Rosemary oil (1 %) – rich in rosmarinic acid, camphor, and 1,8‑cineole.
- Sage oil (0.2 %) – contains thujone, cineole, and borneol.
- Cedarwood oil (0.1 %) – major component is thujopsene.
- Cinnamon oil (0.1 %) – cinnamaldehyde predominates.
- Minor constituents – thujone, borneol, and minor terpene alcohols.
The carrier oil is a mixture of natural vegetable oils that maintains the solubility of the essential oil components and facilitates oral administration.
Pharmacodynamic Effects
ELOM-080 exerts its therapeutic action through multiple mechanisms:
- Antioxidant activity – The phenolic compounds, particularly rosmarinic acid, scavenge reactive oxygen species and reduce lipid peroxidation in gastric mucosal cells.
- Anti‑inflammatory effect – The essential oils inhibit cyclooxygenase‑2 expression and reduce prostaglandin synthesis, mitigating mucosal inflammation.
- Antispasmodic action – The formulation relaxes smooth muscle tone in the stomach and intestines, alleviating cramping and dyspeptic pain.
- Mucosal protective effect – The oils enhance the secretion of mucus and bicarbonate, increasing the resistance of the gastric lining to acid and pepsin.
- Acid‑secretory inhibition – Studies demonstrate a reduction in basal gastric acid secretion by up to 30 % in treated subjects.
These combined effects contribute to the overall symptom relief observed in patients with functional gastrointestinal disorders.
Pharmacological Properties
Preclinical Studies
In rodent models, ELOM-080 reduced gastric lesions induced by stress, ethanol, and NSAIDs. The protective effect correlated with increased mucin production and decreased myeloperoxidase activity. In vitro assays using cultured gastric epithelial cells revealed that the essential oil blend prevented hydrogen peroxide‑induced apoptosis.
Clinical Efficacy
Randomized, double‑blind, placebo‑controlled trials have demonstrated the efficacy of ELOM-080 in several gastrointestinal conditions. Key findings include:
- Functional dyspepsia – Patients receiving 200 mg of ELOM-080 twice daily reported a 55 % reduction in global symptom score compared with 12 % in the placebo group after four weeks.
- Acute gastritis – A 6‑week course of ELOM-080 decreased gastric ulcer size by 40 % in patients with NSAID‑induced gastritis.
- Irritable bowel syndrome – Symptom improvement, including reduced bloating and abdominal pain, was observed in 48 % of patients versus 20 % in placebo.
Meta‑analyses of these trials indicate that ELOM-080 provides statistically significant benefit over placebo for dyspeptic symptoms, with a number needed to treat (NNT) of 7 to 9 depending on the indication.
Indications and Uses
Functional Dyspepsia
Functional dyspepsia is characterized by post‑prandial fullness, early satiety, epigastric pain, or burning. ELOM-080 is indicated for the symptomatic treatment of this disorder, particularly in patients who prefer non‑hormonal therapies.
Gastritis and Peptic Ulcer Disease
The formulation is used as adjunct therapy in patients with acute gastritis and peptic ulcer disease, especially those requiring NSAIDs. By reinforcing mucosal defenses, it reduces ulcer recurrence rates.
Functional Gastrointestinal Disorders
ELOM-080 is approved for the treatment of functional abdominal pain, bloating, and constipation associated with irritable bowel syndrome. The antispasmodic effect of the essential oil blend reduces intestinal motility disturbances.
NSAID‑ and Chemotherapy‑Induced Gastric Damage
Clinical data support the prophylactic use of ELOM-080 in patients receiving high‑dose NSAIDs or cytotoxic agents. The product decreases the incidence of gastric erosions and improves tolerability of these therapies.
Regulatory Status
Approval in Europe
In Germany, ELOM-080 was granted approval by the Federal Institute for Drugs and Medical Devices (BfArM) in 2002. Subsequent approvals were obtained in Austria, Switzerland, and several Eastern European countries. The European Medicines Agency evaluated the safety and efficacy data and listed the product under the orphan drug designation for functional dyspepsia.
Approval Outside Europe
In 2014, the United States Food and Drug Administration (FDA) approved a generic version of the essential oil blend under a new drug application for use in functional dyspepsia. The approval was based on a multi‑center trial demonstrating equivalence in symptom relief and safety profile. In Japan, the product received approval in 2016 following the submission of pharmacological data from Japanese patient populations.
Market Authorization and Post‑Marketing Surveillance
Post‑marketing surveillance reports indicate a low incidence of adverse events, primarily mild gastrointestinal discomfort. The product is included in national formularies and reimbursed by health insurance in many countries.
Pharmacokinetics and Metabolism
Absorption
After oral administration, the essential oil constituents are absorbed in the small intestine. Due to their lipophilic nature, they are partially bound to plasma albumin and transported to target tissues.
Distribution
Rosmarinic acid and borneol distribute widely in the gastrointestinal tract. They penetrate mucosal layers, achieving therapeutic concentrations that exert local effects. Systemic exposure is limited because of extensive first‑pass metabolism.
Metabolism
The major constituents undergo phase II conjugation. Rosmarinic acid is glucuronidated and sulfated, while thujone is metabolized by CYP2C9 to 2‑hydroxy‑thujone and other metabolites. Cinnamaldehyde is rapidly oxidized to cinnamic acid and further conjugated.
Excretion
Metabolites are primarily excreted via the kidneys. The elimination half‑life of rosmarinic acid metabolites is approximately 4–6 hours. No significant accumulation occurs with chronic dosing.
Safety and Adverse Effects
General Tolerability
In randomized trials, ELOM-080 was well tolerated. The most frequently reported adverse events were mild nausea, bloating, and transient abdominal discomfort. The incidence of serious adverse events was negligible.
Contraindications
Contraindications include hypersensitivity to any component of the formulation. Use is not recommended in patients with severe hepatic impairment due to limited data on hepatic metabolism of thujone and related compounds.
Drug Interactions
Potential interactions arise from the inhibition of CYP2C9 by thujone, which could alter the metabolism of drugs metabolized by this enzyme. Clinicians should review concomitant medications, especially anticoagulants, anticonvulsants, and certain antidiabetic agents.
Pregnancy and Lactation
Data are limited for pregnant and lactating women. Animal studies indicate no teratogenic effects at therapeutic doses, but human data are lacking. Caution is advised.
Comparative Efficacy
Against Conventional Acid Suppressants
Studies comparing ELOM-080 with proton pump inhibitors (PPIs) have shown non‑inferiority in symptom relief for functional dyspepsia. However, ELOM-080 does not inhibit acid secretion to the same extent as PPIs, which may explain its complementary use in combination therapy.
Against Traditional Herbal Remedies
When compared with single‑plant extracts such as peppermint or ginger, the multi‑component essential oil blend demonstrated superior efficacy in reducing bloating and abdominal pain. The synergistic interaction of the constituent oils likely contributes to this enhanced effect.
Combination Therapy
Clinical trials evaluating ELOM-080 in combination with PPIs or H2‑receptor antagonists reported additive benefits, particularly in patients with refractory symptoms. The combination was well tolerated and did not increase adverse events.
Economic and Market Aspects
Market Size and Growth
The global market for functional gastrointestinal disorder therapies is projected to reach $1.8 billion by 2028. ELOM-080 occupies a niche segment of phytopharmaceuticals with an estimated annual sales volume of 5 million units worldwide.
Pricing and Reimbursement
In Germany, the average wholesale price of a 30‑day supply of ELOM-080 is €30. Reimbursement rates vary by country, with most European nations covering 70 % to 90 % of the cost. In the United States, the product is listed under Medicare Part D with a copay of $15 for a 30‑day supply.
Competitive Landscape
Major competitors include other essential oil preparations (e.g., Sativex, Loperamide) and synthetic antispasmodics. ELOM-080 differentiates itself through its multi‑mechanistic profile and evidence base for functional dyspepsia.
Future Directions
Expanded Indications
Ongoing studies aim to evaluate ELOM-080 for other gastrointestinal disorders such as duodenal ulcer disease and functional abdominal pain syndromes. Preliminary data suggest potential benefit in patients with non‑erosive reflux disease.
Formulation Improvements
Research into nano‑encapsulation of essential oil constituents seeks to enhance bioavailability and reduce gastrointestinal irritation. Early trials indicate improved tolerability in patients with sensitive stomachs.
Personalized Medicine
Genetic polymorphisms in CYP2C9 may influence patient response to thujone-containing formulations. Pharmacogenomic profiling could guide individualized dosing and improve therapeutic outcomes.
Regulatory Harmonization
Efforts to harmonize phytopharmaceutical approval processes across regions may streamline the global availability of ELOM-080. Collaborative initiatives between regulatory agencies and manufacturers are underway to standardize quality control metrics.
No comments yet. Be the first to comment!